38308-93-9Relevant academic research and scientific papers
Synthesis and immunobiological activity of an original series of acyclic lipid A mimics based on a pseudodipeptide backbone
Martin, Olivier R.,Zhou, Wei,Wu, Xinfu,Front-Deschamps, Sophie,Moutel, Stéphane,Schindl, Katharina,Jeandet, Patricia,Zbaeren, Claude,Bauer, Jacques A.
, p. 6000 - 6014 (2007/10/03)
Nδ-L-Homoserinyl-D-ornithinol pseudodipeptides N-acylated with typical Escherichia coli lipid A fatty acid residues and mono-O- or bis-O-phosphorylated have been prepared and their properties investigated. The derivatives carrying two phosphate groups were found to be inducers of NO production. In addition, while they were unable to induce significantly the production of interleukin-6 (IL-6) by human PBMC cells, these compounds behaved also as potent antagonists of LPS-induced IL-6 production in the same human cells system. In conclusion, the molecules described here are the first members of an original class of immunobiologically active lipid A mimics based on an acyclic pseudodipeptide backbone carrying only the essential functionalities of the parent lipid A structure (OM-174). As the products exhibit very low endotoxicity and pyrogenicity, this class of lipid A mimics therefore opens a new generation of immunoadjuvants that possibly could reach clinical applications.
Novel acyl-dipeptide-like compounds, a method for preparing the same and pharmaceutical compositions containing such products
-
Page/Page column 5, (2008/06/13)
The invention relates to the field of chemistry and more specifically to the field of medicinal chemistry. The invention is directed to N-acyl-dipeptide-like compounds having the general formula I wherein substituents A, B, X, Y, R1, R2, and subscripts n, m, p and q have the same meanings as those given in the claims. The invention is equally directed to pharmaceutical compositions containing as an active ingredient at least one compound of general formula I either in acid or salt form with an organic or mineral base. The compounds persuant to the invention display interesting pharmacological properties which make them useful as drugs.
Sulfonamide derivatives
-
Page column 144, (2010/02/05)
A compound of the formula (I) or a pharmacologically acceptable salt, ester or other derivative thereof: R1is H or NHOH. R2is H, optionally substituted alkyl, cycloalkyl or a group —AR6. A is an alkylene which may be optionally interrupted by O, —S(O)m— or —N(R9). R6is a group (II), (III), (IV) X is O, S, —N(R10)—, —C(R11)(R12)—. Y is O, CO, —S(O)n—, —N(R10)—, —C(R11)(R12)—. Each of R7and R8is H, alkyl, COOH, optionally substituted alkyl, etc. Each of R9, R10, R11, and R12is H, alkyl, etc. Each of m and n is 0 to 2. R3is H, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted alkenyl, optionally substituted alkynyl. R4is optionally substituted (hetero)arylene. R5is optionally substituted alkyl, optionally substituted (hetero)aryl. These compounds have matrixmetalloproteinase—13 inhibitory activity and aglycanase inhibitory activity.
SULFONAMIDE DERIVATIVES
-
, (2008/06/13)
The object is to provide a compound having matrixmetalloproteinase-13 inhibitory activity and aglycanase inhibitory activity. A compound of the following formula (I) or a pharmacologically acceptable salt, ester or other derivative thereof:{R1: H, NHOH; R2: H, optionally substituted alkyl, cycloalkyl, a group -AR6 [A: an alkylene which may be optionally interrupted by O, -S(O)m- or -N(R9); R6: a group (II), (III), (IV)X: O, S, -N(R10)-, -C(R11)(R12)-; Y: O, CO, -S(O)n-, -N(R10)-, -C(R11)(R12)-; R7, R8: H, alkyl, COOH, optionally subsituted alkyl, etc.; R9, R10, R11,R12: H, alkyl, etc.; m, n: 0 to 2]R3: H, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted alkenyl, optionally substituted alkynyl; R4: optionally substituted (hetero)arylene; R5: optionally substituted alkyl, optionally substituted (hetero)aryl}.
